Mifepristone for uterine fibroids.

ABSTRACT:

Background

Uterine fibroids are the most common benign uterine tumours present in women of reproductive age. Mifepristone (RU-486) competitively binds and inhibits progesterone receptors. Studies have suggested that fibroid growth depends on the sexual steroids. Mifepristone has been shown to decrease fibroid size. This review summarises the effects of mifepristone treatment on fibroids and the associated adverse effects as described in randomised controlled trials.

Objectives

To determine the efficacy and safety of mifepristone for the management of uterine fibroids in pre-menopausal women.

Search methods

We searched the specialised register of the Cochrane Menstrual Disorders and Subfertility (Cochrane Menstrual Disorders and subfertility Review Group), the Cochrane

SUBMITTER: Tristan M 

PROVIDER: S-EPMC8212859 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature